Actor portrayal

Hand holding ZORYVE topical foam canister
Hand holding ZORYVE topical foam canister

Study Design

DESIGNED FOR CLEARANCE—ANYWHERE1-3

Study participants reflected everyday patients

  • Two multicenter, randomized, double-blind, vehicle-controlled studies (Trial 203 and STRATUM)
  • 683 participants with moderate to severe seborrheic dermatitis
    • STRATUM: ZORYVE foam = 304, vehicle = 153
    • Trial 203: ZORYVE foam = 154, vehicle = 72
  • Once daily for 8 weeks
  • Evaluated as monotherapy; no concomitant therapies were allowed
Vehicle QD(n=225)8 weeks dosingZORYVE (roflumilast) foam 0.3% QD(n=458)N=683Randomized2:1
See eligibility criteria

One foam.
Once a day. Anywhere.

Scalp of African American person with Seborrheic Dermatitis

SCALP

Face with Seborrheic Dermatitis from an actual trial patient

FACE

Closed eyelid with Seborrheic Dermatitis from an actual trial patient

EYELIDS

Ear with Seborrheic Dermatitis from an actual trial patient

EARS

Trunk (man’s chest) with Seborrheic Dermatitis from an actual trial patient

TRUNK

Actual clinical trial patients

73% of patients had involvement in multiple areas in STRATUM2

Primary Endpoint

Key Secondary Endpoints
In STRATUM

IGA Success
(Clear or Almost Clear)
at WEEK 8

Achievement of an IGA score of Clear/Almost Clear and a ≥2-grade improvement from baseline

Actor portrayal

IGA = Investigator Global Assessment.

Completely Clear at WEEK 8

Achievement of completely Clear skin (IGA = 0)

WI-NRS Success (Itch Improvement) at WEEK 8

Achievement of a ≥4-point improvement for patients with a baseline score of ≥4

Actor portrayal

IGA = Investigator Global Assessment.

WI-NRS = Worst-Itch Numeric Rating Scale.

See the Efficacy Data
View Safety Profile
Request a Representative